<DOC>
	<DOCNO>NCT00149877</DOCNO>
	<brief_summary>Tegaserod ( HTF919 ) aminoguanidine indole compound member new class subgroup-selective 5-hydroxytryptamine ( 5-HT ) agonist . The aim study investigate efficacy , safety tolerability tegaserod bowel habit patient CC .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Tegaserod Patients With Chronic Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>Male female least 18 year age A 12month history constipation ( define &lt; three spontaneous bowel movement per week â‰¥1 follow symptom &gt; 25 % time : hard stool , sensation incomplete evacuation strain ) Patients cancer , inflammatory bowel disease structural bowel disease Patients participate prior tegaserod study Evidence cathartic colon laxative abuse , pelvic floor dysfunction neurological disorder Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Chronic constipation , tegaserod</keyword>
</DOC>